A conversation with Geneoscopy Chief Science and Medical Officer Erica Barnell, MD, Ph.D. For most trials slated in 2020, and even in some later pandemic years, enrollment delays were inevitable. The restriction of in-person activities or, if they were allowed, the imposition of social distancing guidelines, negatively affected patients’ ability to participate in or interest in enrolling in clinical trials. Yet, Geneoscopy forged ahead with its Phase 3 trial (CRC-PREVENT) for ColoSense…
